Tami Rachmilewitz
Keine laufenden Positionen mehr
Profil
Tami Rachmilewitz worked as the Medical Director & Head-Pharmacovigilance at NeuroDerm Ltd.
from 2016 to 2018.
She then served as the Senior Vice President-Clinical Development at Vascular Biogenics Ltd.
in 2022.
In 2023, she was the Chief Medical Officer at BioLineRx Ltd.
Dr. Rachmilewitz obtained her undergraduate degree from The Hebrew University of Jerusalem and her doctorate from The Hebrew University Hadassah Medical School.
Ehemalige bekannte Positionen von Tami Rachmilewitz
| Unternehmen | Position | Ende |
|---|---|---|
| BIOLINERX LTD. | Chief Tech/Sci/R&D Officer | 01.10.2023 |
| NOTABLE LABS, LTD. | Chief Tech/Sci/R&D Officer | 01.12.2022 |
| NEURODERM LTD | Chief Tech/Sci/R&D Officer | 01.01.2018 |
Ausbildung von Tami Rachmilewitz
| The Hebrew University of Jerusalem | Undergraduate Degree |
| The Hebrew University Hadassah Medical School | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BIOLINERX LTD. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
NeuroDerm Ltd.
 NeuroDerm Ltd. BiotechnologyHealth Technology NeuroDerm Ltd. operates as a clinical-stage pharmaceutical company. It engages in the development of next-generation treatments for central nervous system disorders. The company was founded by Eliahu Heldman on March 18, 2003 and is headquartered in Rehovot, Israel. | Health Technology |
Vascular Biogenics Ltd.
 Vascular Biogenics Ltd. BiotechnologyHealth Technology Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel. | Health Technology |
